CD8A and neoplasm: Liu Hongzhuo developed an injectable delivery platform (Tel@PGE) to deliver Tel to the tumor resection site, which can lead to more infiltration of CD8+T cells and DCs in the tumor tissue and draining lymph nodes, convert M2 macrophages to M1 macrophages, and make the tumor change from “cold” to “hot” and trigger a strong local and systemic immune response at the resection site, inhibit postoperative tumor recurrence and metastasis, improve the survival rate of B16F10 and 4T1 tumor models (Liu et al., 2022a).